Breaking News Instant updates and real-time market news.

PRTK

Paratek Pharmaceuticals

$9.73

0.08 (0.83%)

, AGN

Allergan

$192.36

1.92 (1.01%)

08:50
10/02/18
10/02
08:50
10/02/18
08:50

Paratek Pharmaceuticals receives FDA approval for Seysara

Paratek Pharmaceutical (PRTK) announced that the FDA has approved Seysara for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Paratek has exclusively licensed U.S. development and commercialization rights of Seysara for the treatment of acne to Allergan (AGN), who has assigned such rights to Almirall. Paratek retains development and commercialization rights in the rest of the world. Seysara is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory properties for the potential treatment of moderate to severe acne in the community setting. Under the parties' agreement, Paratek earned a $12M milestone payment upon FDA approval and is now entitled to receive tiered royalties at rates ranging from high-single to low double digits on net sales of Seysara.

PRTK

Paratek Pharmaceuticals

$9.73

0.08 (0.83%)

AGN

Allergan

$192.36

1.92 (1.01%)

  • 03

    Oct

  • 30

    Oct

PRTK Paratek Pharmaceuticals
$9.73

0.08 (0.83%)

08/27/18
BOFA
08/27/18
INITIATION
Target $13
BOFA
Neutral
Paratek Pharmaceuticals initiated with a Neutral at BofA/Merrill
BofA/Merrill analyst Jason Gerberry initiated Paratek Pharmaceuticals with a Neutral and $13 price target.
08/09/18
WEDB
08/09/18
NO CHANGE
Target $20
WEDB
Tone of Paratek advisory committee meeting 'extremely positive,' says Wedbush
Wedbush analyst Robert Driscoll said the tone of yesterday's antimicrobials drug advisory committee meeting was "extremely positive" regarding to the data presented by Paratek and he expects full approval of omadacycline for the treatment of both acute bacterial skin infections and community-acquired bacterial pneumonia in early October. He believes the flexible dosing, low risk of C. difficile and lack of drug-drug interactions will support significant commercial success of omadacycline. Driscoll keeps an Outperform rating and $20 price target on Paratek shares.
08/08/18
RAJA
08/08/18
NO CHANGE
RAJA
Outperform
AdCom vote increases chances of Paratek's omadacycline approval, says Raymond James
Raymond James analyst Laura Chico notes that the FDA's Advisory Committee voted 17-1 in favor of approval for Paratek Pharmaceuticals' omadacycline in skin infections and 14-4 in favor of approval in pneumonia. While the analyst acknowledges that the FDA is not bound by the committee's decision, they nearly always follow the recommendation. Thus, she thinks the vote incrementally increases the chances for an omadacycline approval. Chico reiterates an Outperform rating on the shares.
08/06/18
HCWC
08/06/18
NO CHANGE
Target $55
HCWC
Buy
Paratek risk/reward favorable into Wednesday's panel, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce believes the risk/reward for Paratek Pharmaceuticals is "positively-skewed" into Wednesday's FDA panel meeting for omadacycline. The analyst expects a "relatively smooth" panel and would be buyers of the stock heading into the early October FDA action date. Arce keeps a Buy rating on Paratek with a $55 price target.
AGN Allergan
$192.36

1.92 (1.01%)

09/27/18
MZHO
09/27/18
NO CHANGE
Target $48
MZHO
Buy
Revance selloff on Allergan data a buying opportunity, says Mizuho
Mizuho analyst Difei Yang says that while Allergan's (AGN) new data from a Phase 1b trial of higher dose Botox in moderate-to-severe glabellar lines showed better duration relative to the standard dose Botox, Revance Therapeutics (RVNC) remains best positioned to address the long-duration botulinum toxin products market. The analyst believes the weakness in Revance shares during 2018 has created buying opportunities. The analyst reiterates a Buy rating on the stock with a $48 price target.
09/18/18
CANT
09/18/18
NO CHANGE
Target $35
CANT
Overweight
Evolus selloff yesterday not based on fundamentals, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen sees no fundamental reason for the 12% pullback yesterday in shares of Evolus (EOLS). The stock weakness was partly attributed to the "upbeat and well-attended" investor day held by competitor Allergan (AGN) last Friday, Chen tells investors in a research note. The analyst points out that shares of Revance (RVNC), which also competes with Allergan in the botulinum toxin space, dropped yesterday as well. Chen believes Allergan's investor day renewed concerns that the company is and will remain the leading botulinum toxin/aesthetics player in the space. However, this is nothing new and is already priced into Evolus' valuation, Chen contends. The analyst continues to expect the company's launch of DWP-450 in spring 2019 to exceed "modest expectations." She keeps an Overweight rating on the shares with a $35 price target.
09/17/18
RHCO
09/17/18
NO CHANGE
Target $218
RHCO
Buy
Allergan price target raised to $218 from $200 at SunTrust
SunTrust analyst John Boris raised his price target on Allergan to $218 and kept his Buy rating, saying the company's Medical Aesthetics Day presentation on Friday supports his view that its markets are "materially under-penetrated". The analyst is positive on the company's portfolio, pipeline, and commercial investment that includes a salesforce expansion of over 20% for Botox/Juvederm and CoolSculpting, which he contends should "allay competitive fears". Boris adds that he is keeping his earnings view for FY18-19, but raises his global sales forecast by FY25 by $880M to $7B.
09/17/18
09/17/18
DOWNGRADE

Market Perform
Revance downgraded to Market Perform after Allergan data at JMP Securities
As previously reported, JMP Securities analyst Donald Ellis downgraded Revance (RVNC) to Market Perform from Outperform after Allergan (AGN) released Botox study data that he said suggests that the longer duration of activity of Revance's RT002 may be partially or primarily due to a "dose" effect. While Ellis doesn't see Allergan conducting the trials needed for an FDA label change, he does think the data will be extensively shared at medical meetings and sees it minimizing the benefit of extended duration claims for RT002 versus Botox.

TODAY'S FREE FLY STORIES

FND

Floor & Decor

$37.71

0.93 (2.53%)

11:54
02/21/19
02/21
11:54
02/21/19
11:54
Recommendations
Floor & Decor analyst commentary  »

Floor & Decor target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 07

    Mar

AGI

Alamos Gold

$4.84

-0.03 (-0.62%)

11:50
02/21/19
02/21
11:50
02/21/19
11:50
Options
Alamos Gold attracts calls sold after an analyst downgrade »

Alamos Gold attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

MDT

Medtronic

$92.39

-0.41 (-0.44%)

11:46
02/21/19
02/21
11:46
02/21/19
11:46
Conference/Events
Medtronic participates in a conference call with JPMorgan »

Healthcare Analyst Marcus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 06

    Mar

  • 18

    May

  • 28

    May

S

Sprint

$6.43

0.115 (1.82%)

11:45
02/21/19
02/21
11:45
02/21/19
11:45
Options
Sprint call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 11

    Mar

  • 11

    Mar

BIIB

Biogen

$322.54

-12.47 (-3.72%)

, RHHBY

Roche

$0.00

(0.00%)

11:44
02/21/19
02/21
11:44
02/21/19
11:44
On The Fly
Biogen downgrade, cannabis sector initiation among today's top analyst calls »

Check out today's top…

BIIB

Biogen

$322.54

-12.47 (-3.72%)

RHHBY

Roche

$0.00

(0.00%)

X

U.S. Steel

$24.06

0.06 (0.25%)

AAN

Aaron's

$53.84

0.2 (0.37%)

BBY

Best Buy

$60.11

-0.15 (-0.25%)

DHI

D.R. Horton

$39.76

-0.11 (-0.28%)

LEN

Lennar

$48.81

-0.15 (-0.31%)

APHA

Aphria

$10.33

0.17 (1.67%)

KSHB

KushCo Holdings

$0.00

(0.00%)

HEXO

HEXO Corp

$5.89

-0.09 (-1.51%)

CGC

Canopy Growth

$45.25

-0.93 (-2.01%)

ACB

Aurora Cannabis

$7.07

0.01 (0.14%)

TLRY

Tilray

$79.49

-1.58 (-1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 25

    Feb

  • 27

    Feb

  • 03

    Mar

  • 04

    Mar

  • 05

    Mar

  • 05

    Mar

  • 06

    Mar

  • 11

    Mar

  • 18

    Mar

  • 18

    Mar

  • 18

    Mar

  • 04

    Apr

  • 28

    May

  • 19

    Aug

MNSB

MainStreet Bancshares

$0.00

(0.00%)

11:42
02/21/19
02/21
11:42
02/21/19
11:42
Hot Stocks
MainStreet Bancshares applies to list common stock on NASDAQ Capital Market »

MainStreet Bancshares,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZSAN

Zosano Pharma

$4.19

1.98 (89.59%)

11:40
02/21/19
02/21
11:40
02/21/19
11:40
Recommendations
BTIG boosts Zosano target to $19 on 'solid' migraine safety data »

BTIG analyst Robert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:38
02/21/19
02/21
11:38
02/21/19
11:38
General news
4-Week Bill Auction Total Amount data reported »

4-Week Bill Auction Total…

11:38
02/21/19
02/21
11:38
02/21/19
11:38
General news
8-Week Bill Auction Total Amount data reported »

8-Week Bill Auction Total…

UNIT

Uniti Group

$11.23

-1.035 (-8.44%)

11:35
02/21/19
02/21
11:35
02/21/19
11:35
Options
Uniti Group put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 11

    Mar

  • 11

    Mar

ZSAN

Zosano Pharma

$3.89

1.68 (76.02%)

11:32
02/21/19
02/21
11:32
02/21/19
11:32
Hot Stocks
Breaking Hot Stocks news story on Zosano Pharma »

Zosano Pharma jumps 100%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:31
02/21/19
02/21
11:31
02/21/19
11:31
Conference/Events
UBS leisure/lodging analyst to hold an analyst/industry conference call »

Leisure, Gaming &…

ZSAN

Zosano Pharma

$3.89

1.68 (76.02%)

11:31
02/21/19
02/21
11:31
02/21/19
11:31
Hot Stocks
Zosano says Qtrypta long-term study shows 'well-tolerated safety profile' »

Zosano Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZYNE

Zynerba

$4.85

-0.05 (-1.02%)

11:31
02/21/19
02/21
11:31
02/21/19
11:31
Hot Stocks
Zynerba patent listed by World Intellectual Property Organization »

The patent listed by the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$24.23

-0.45 (-1.82%)

11:25
02/21/19
02/21
11:25
02/21/19
11:25
Options
JD.com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 04

    Mar

  • 20

    Mar

KMTUY

Komatsu

$0.00

(0.00%)

11:21
02/21/19
02/21
11:21
02/21/19
11:21
Downgrade
Komatsu rating change  »

Komatsu downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:20
02/21/19
02/21
11:20
02/21/19
11:20
General news
Treasury announced $113 B in shorter dated coupon sales for next week »

Treasury announced $113 B…

SCI

Service Corp.

$42.31

-0.42 (-0.98%)

11:17
02/21/19
02/21
11:17
02/21/19
11:17
Hot Stocks
Service Corp. raises quarterly cash dividend 6% to 18c per share »

Service Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
02/21/19
02/21
11:17
02/21/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
02/21/19
02/21
11:16
02/21/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
02/21/19
02/21
11:15
02/21/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

11:15
02/21/19
02/21
11:15
02/21/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

GS

Goldman Sachs

$197.12

-1.49 (-0.75%)

11:10
02/21/19
02/21
11:10
02/21/19
11:10
Initiation
Goldman Sachs initiated  »

Odeon's Dick Bove…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

  • 12

    Mar

11:10
02/21/19
02/21
11:10
02/21/19
11:10
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

DK

Delek US

$36.95

-0.13 (-0.35%)

11:10
02/21/19
02/21
11:10
02/21/19
11:10
Options
Delek US draws upside call buyers as shares slip off early highs »

Delek US draws upside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.